GTR Test Accession:
Help
GTR000558498.5
CAP
Last updated in GTR:
2021-01-19
View version history
GTR000558498.5,
last updated:
2021-01-19
GTR000558498.4,
last updated:
2020-08-17
GTR000558498.3,
last updated:
2019-08-13
GTR000558498.2,
last updated:
2018-08-20
GTR000558498.1,
registered in GTR:
2017-11-20
Last annual review date for the lab: 2024-07-22
LinkOut
At a Glance
Test purpose:
Help
Diagnosis;
Monitoring;
Mutation Confirmation; ...
Conditions (37):
Help
Acute myeloid leukemia;
Ataxia-pancytopenia syndrome;
Autosomal dominant aplasia and myelodysplasia
more...
Genes (85):
Help
Methods (2):
Help
Molecular Genetics - Deletion/duplication analysis: Next-Generation (NGS)/Massively parallel sequencing (MPS); ...
Target population: Help
Not provided
Clinical validity:
Help
Not provided
Clinical utility:
Help
Establish or confirm diagnosis
Ordering Information
Offered by:
Help
Specimen Source:
Help
- Buccal swab
- Cord blood
- Fibroblasts
- Peripheral (whole) blood
- Saliva
- Skin
- View specimen requirements
Who can order: Help
- Genetic Counselor
- Health Care Provider
- Licensed Physician
- Nurse Practitioner
- Physician Assistant
- Registered Nurse
Test Order Code:
Help
CPT codes:
Help
Contact Policy:
Help
Laboratory can only accept contact from health care providers. Patients/families are encouraged to discuss genetic testing options with their health care provider.
How to Order:
Help
•All samples should be shipped via overnight delivery at room temperature.
•No weekend or holiday deliveries.
•Label each specimen with the patient’s name, date of birth and date sample collected.
•Send specimens with complete requisition and consent form, otherwise, specimen processing may be delayed.
Order URL
•No weekend or holiday deliveries.
•Label each specimen with the patient’s name, date of birth and date sample collected.
•Send specimens with complete requisition and consent form, otherwise, specimen processing may be delayed.
Order URL
Test service:
Help
Clinical Testing/Confirmation of Mutations Identified Previously
Confirmation of research findings
Confirmation of research findings
Test additional service:
Help
Custom Prenatal Testing
Custom mutation-specific/Carrier testing
Custom mutation-specific/Carrier testing
Test development:
Help
Test developed by laboratory (no manufacturer test name)
Informed consent required:
Help
No
Pre-test genetic counseling required:
Help
Decline to answer
Post-test genetic counseling required:
Help
Decline to answer
Recommended fields not provided:
Lab contact for this test,
Test strategy
Conditions
Help
Total conditions: 37
| Condition/Phenotype | Identifier |
|---|
Test Targets
Genes
Help
Total genes: 85
| Gene | Associated Condition | Germline or Somatic | Allele (Lab-provided) | Variant in NCBI |
|---|
Methodology
Total methods: 2
Method Category
Help
Test method
Help
Instrument *
Deletion/duplication analysis
Next-Generation (NGS)/Massively parallel sequencing (MPS)
Sequence analysis of the entire coding region
Next-Generation (NGS)/Massively parallel sequencing (MPS)
* Instrument: Not provided
Clinical Information
Test purpose:
Help
Diagnosis;
Monitoring;
Mutation Confirmation;
Pre-symptomatic;
Risk Assessment;
Screening
Clinical utility:
Help
Establish or confirm diagnosis
View citations (1)
- Rapid infusion of sodium bicarbonate and albumin into high-risk premature infants soon after birth: a controlled, prospective trial. Bland RD, et al. Am J Obstet Gynecol. 1976;124(3):263-7. doi:10.1016/0002-9378(76)90154-x. PMID: 1. Churpek, J.E., et al., Proposal for the clinical detection and management of patients and their family members with familial myelodysplastic syndrome/acute leukemia predisposition syndromes. Leuk Lymphoma, 2013. 54(1): p. 28-35. 2. Bannon, S.A. and C.D. DiNardo, Hereditary Predispositions to Myelodysplastic Syndrome. Int J Mol Sci, 2016. 17(6). 3. Babushok, D.V., M. Bessler, and T.S. Olson, Genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia in children and young adults. Leuk Lymphoma, 2016. 57(3): p. 520-36. 4. Owen, C., M. Barnett, and J. Fitzgibbon, Familial myelodysplasia and acute myeloid leukaemia--a review. Br J Haematol, 2008. 140(2): p. 123-32. 5. Babushok, D.V. and M. Bessler, Genetic predisposition syndromes: when should they be considered in the work-up of MDS? Best Pract Res Clin Haematol, 2015. 28(1): p. 55-68. 6. Arber, D.A., et al., The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leuke.
Variant Interpretation:
What is the protocol for interpreting a variation as a VUS?
Help
Variants are identified and evaluated using a custom collection of bioinformatic tools and comprehensively interpreted by our team of directors and genetic counselors.
Variants are identified and evaluated using a custom collection of bioinformatic tools and comprehensively interpreted by our team of directors and genetic counselors.
Will the lab re-contact the ordering physician if variant interpretation changes?
Help
Yes.
Yes.
Research:
Is research allowed on the sample after clinical testing is complete?
Help
http://dnatesting.uchicago.edu/research-consent-form
http://dnatesting.uchicago.edu/research-consent-form
Recommended fields not provided:
Clinical validity,
Target population,
Are family members with defined clinical status recruited to assess significance of VUS without charge?,
Sample negative report,
Sample positive report
Technical Information
Availability:
Help
Tests performed
Entire test performed in-house
Entire test performed in-house
Analytical Validity:
Help
Analytical Sensitivity 99-100%
Accuracy 100%
Precision 100%
Assay limitations:
Help
This assay covers the coding and immediate flanking regions of the included genes. Variants in the promoter region and in other non-coding regions will not be detected. Variants that occur within regions of high homology and/or repetitiveness may not be detected due to issues with alignment. The technical sensitivity of …
View more
Proficiency testing (PT):
Is proficiency testing performed for this test?
Help
Yes
Method used for proficiency testing: Help
Formal PT program
PT Provider: Help
American College of Medical Genetics / College of American Pathologists, ACMG/CAP
Yes
Method used for proficiency testing: Help
Formal PT program
PT Provider: Help
American College of Medical Genetics / College of American Pathologists, ACMG/CAP
VUS:
Laboratory's policy on reporting novel variations
Help
All novel and/or potentially pathogenic variants are confirmed by Sanger sequencing
All novel and/or potentially pathogenic variants are confirmed by Sanger sequencing
Recommended fields not provided:
Test Confirmation,
Citations to support assay limitations,
Description of internal test validation method,
Citations for Analytical validity,
Description of PT method,
Major CAP category, CAP category, CAP test list
Regulatory Approval
FDA Review:
Help
Category:
FDA exercises enforcement discretion
Additional Information
Clinical resources:
Molecular resources:
Practice guidelines:
IMPORTANT NOTE:
NIH does not independently verify information submitted to GTR; it relies on submitters to provide information that is accurate and not misleading.
NIH makes no endorsements of tests or laboratories listed in GTR. GTR is not a substitute for medical advice.
Patients and consumers
with specific questions about a genetic test should contact a health care provider or a genetics professional.